- Year over Year Revenue up 74%,
EBITDA up 46% and Adjusted EBITDA up 35% -
TORONTO and DUREN, Germany, Nov. 28,
2022 /CNW/ - GBLT Corp. (TSXV: GBLT)
("GBLT" or the "Company") is pleased to announce its
results for the three and nine-month periods ended September 30th, 2022.
"We continue to focus on our business through expanding our
market share and focusing on growing revenue and bottom line
margins," said Dr. Thilo Senst, CEO
of GBLT. "We have been and continue to grow our product line
presence and with the momentum we are currently experiencing, we
are confident in finishing the year very strong. We will continue
to drive this momentum as the abundance of demand for our products
and solutions continues to grow and we are working diligently to
capitalize on the opportunity, especially for our high margin Dr.
Senst Healthcare and our renewable energy solutions that will drive
GBLT's bottom line growth for the foreseeable future."
Three months ended September 30,
2022, comparted to the three months ended September 30, 2021
- Revenue for the three-month period ended September 30th, 2022, increased by 74%
to €13.65 million ($18.84 million
CAD) compared to €7.84 million ($10.81
million CAD) for the same period in 2021. The increase in
revenue was due to increase in customer demand, addition of new
customer orders and the expansion into solar products and more
flexibility on overall pricing for all the products.
- Gross margin for the three-month period ended September 30th, 2022, was 6.3%
compared to 7.3% for the same period in 2021. Although margins are
trending higher overall, as expected the third quarter had some
large low margin orders. We continue to focus on increasing our
margins through price flexibility and the growth of our higher
margin products.
- Gross profit for the three-month period ended September 30th, 2022, increased by 50%
to €0.85 million ($1.17 million CAD)
compared to €0.57 million ($0.74
million CAD) for the same period in 2021.
- Operating expenses for the three-month ended September 30th, 2022, was €0.83
million ($1.14 million CAD) compared
to €0.53 million ($0.97 million CAD)
in the same period last year
- Net income for the three-month period ended September 30th, 2022, was €21,166
($29,209 CAD) compared to €37,833
($52,209 CAD) in the same period in
2021.
- EBITDA for the three-month period ended September 30th, 2022, increased by 46%
to €0.12 million ($0.17 million CAD)
compared to €0.08 million ($0.11
million CAD) for the same period in 2021.
- Adjusted EBITDA for the three-month period ended September 30th, 2022, increased by 35%
to €0.21 million ($0.28 million CAD)
compared to €0.15 million ($0.21
million CAD) for the same period in 2021.
Nine months ended September 30,
2022, comparted to the nine months ended September 30 2021
- Revenue for the first 9 months of 2022 increased by 37% to
€31.8 million ($43.9 million CAD)
compared to €23.2 million ($32.0
million CAD) in 2021. The increase in revenue is due to
increase in customer demands, new customer orders and the expansion
of the solar product line.
- Gross margin for tor the first nine months of 2022 improved to
10.5% compared 9.6% for the same period in 2021. The increase was
due to flexible pricing on our existing products and focusing on
the higher margin product lines.
- Gross profit for the first nine months increased 49% to €3.33
million ($4.60 million CAD) compared
to €2.23 million ($3.08 million CAD)
in 2021.
- Operating expenses for the first nine months of 2022 was €2.55
million ($3.52 million CAD) compared
€1.73 million ($2.39 million CAD) in
2021.
- Net Income for the first nine months of 2022 increased by 55%
to €0.78 million ($0.99 million CAD)
compared to €0.51 million ($0.70
million CAD) in 2021.
- EBITDA for the first nine months of 2022 increased by 69% to
€1.10 million ($1.52 million CAD)
compared to €0.65 million ($0.90
million CAD) in 2021.
- Adjusted EBITDA for the first nine months of 2022 increased by
52% to €1.24 million ($1.71 million
CAD) compared to €0.82 million ($1.13
million CAD) in 2021.
EBITDA
|
|
Three months
ended
September 30,
|
|
Nine months
ended
September 30,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net Income for the
Period
|
€
|
21,166
|
€
|
37,833
|
€
|
782,438
|
€
|
504,794
|
Depreciation
|
|
20,792
|
|
22,365
|
|
61,947
|
|
44,573
|
Interest and financing
fees
|
|
80,778
|
|
24,141
|
|
256,290
|
|
101,378
|
EBITDA
|
|
122,736
|
|
84,339
|
|
1,100,675
|
|
650,745
|
Bad debt
expense
|
|
49,956
|
|
29,303
|
|
159,810
|
|
127,980
|
Currency exchange gain
(loss)
|
|
34,529
|
|
39,808
|
|
(17,257)
|
|
35,376
|
Share based
payments
|
|
-
|
|
-
|
|
-
|
|
5,137
|
Adjusted
EBITDA
|
€
|
207,221
|
€
|
153,450
|
€
|
1,243,228
|
€
|
819,238
|
EBITDA
(CAD)
|
|
Three months
ended
September 30,
|
|
Nine months
ended
September 30,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net Income for the
Period
|
$
|
29,209
|
$
|
52,210
|
$
|
1,079,764
|
$
|
696,616
|
Depreciation
|
|
28,693
|
|
30,864
|
|
85,487
|
|
61,511
|
Interest and financing
fees
|
|
111,474
|
|
33,315
|
|
353,680
|
|
139,902
|
EBITDA
|
|
169,376
|
|
116,388
|
|
1,518,932
|
|
898,028
|
Bad debt
expense
|
|
68,939
|
|
40,438
|
|
220,538
|
|
176,612
|
Currency exchange gain
(loss)
|
|
47,650
|
|
54,935
|
|
(23,815)
|
|
48,819
|
Share based
payments
|
|
-
|
|
|
|
-
|
|
7,089
|
Adjusted
EBITDA
|
$
|
285,965
|
$
|
211,761
|
$
|
1,715,655
|
$
|
1,130,548
|
Source: Bank of Canada
Exchange Rate at 2022-11-18 rate of €1.38 per $1.00
CAD
|
https://www.bankofcanada.ca/rates/exchange/daily-exchange-rates/
|
|
About GBLT:
GBLT Corp., through its operating company,
GBT GmbH, designs, manufactures and supplies mobile storage, and
battery solutions. GBLT is also a leading provider of renewable
energy solutions via its solar division, participating in the
rapidly growing solar energy market. In addition, the Company
offers consumer healthcare and wellness products to some of the
largest retail chains across the globe. GBT is also an official
licensee for AGFAPHOTO mobile energy products. The Company's
branded healthcare and wellbeing products are primarily sold
throughout Europe under Dr. Senst
brand.
For more information, please visit www.gbt-international.com
and www.gbltcorp.com.
Forward-Looking
Information
Certain statements in this news release, which are not
historical in nature, constitute "forward looking statements"
within the meaning of that phrase under applicable Canadian
securities law. These statements include, but are not limited to,
statements or information concerning the Company's proposed
activities under the Agreement, the Company's ability to achieve
sales, commercial or otherwise, from its products, and the
expectations of the Company regarding funding payments due pursuant
to the Agreement. These statements reflect management's current
assumptions and expectations and by their nature are subject to
certain underlying assumptions, known and unknown risks and
uncertainties and other factors which may cause actual results,
performance or events to be materially different from those
expressed or implied by such forward looking statements. Except as
required pursuant to applicable securities laws, the Company will
not update these forward-looking statements to reflect events or
circumstances after the date hereof. More detailed information
about potential factors that could affect financial results is
included in the documents filed from time to time with the Canadian
securities regulatory authorities by the Company. Readers are
cautioned not to place undue reliance on forward looking
statements.
Neither the TSX Venture Exchange nor its
Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE GBLT Corp.